Cellenkos Secures Orphan Drug Designation from FDA for CK0801 to Combat Aplastic Anemia Cellenkos Inc. has received Orphan Drug Designation by the FDA for CK0801, a new treatment for Aplastic Anemia, highlighting significant advancements in biotechnology.

Cellenkos Secures Orphan Drug Designation from FDA for CK0801 to Combat Aplastic Anemia #United_States #Houston #Aplastic_Anemia #Cellenkos #CK0801